Skip to content
Biotechnology

Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

Clairvoyant Therapeutics 3 mins read

Clairvoyant on target for potential commercialization of psilocybin treatment in 2025

VANCOUVER, BC / ACCESSWIRE / April 3, 2024 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the private clinical-stage pharmaceutical company developing psilocybin treatment for alcohol use disorder (AUD), today announced that it is on target to potentially become the first in the world to commercialize clinically validated psilocybin treatment. Clairvoyant believes it may achieve this milestone in H2 2025.

Clairvoyant's randomized controlled trial, CLA-PSY-201, has dosed more than 90 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin treatment for AUD (two dosing sessions of a 25 mg oral capsule over 8 weeks) at 12 active clinical sites in Canada and Europe. A top line read out from the clinical trial is expected in Q3 2024 and a Series A financing round is currently underway.

"We are quickly approaching a critical and exciting moment for psilocybin and its potential use as a recognized treatment," said Damian Kettlewell, CEO, Clairvoyant. "We have the compelling efficacy and safety data on psilocybin treatment for AUD from a phase 2a study previously published in JAMA Psychiatry[i] in 2022 and earlier data published in 2015. Assuming our trial has similar results, we believe there is a regulatory pathway to conditional market authorization in Canada in 2025 and in the EU in 2026."

Conditional marketing authorization of psilocybin would be based on recognition of AUD as a serious, life-threatening or severely debilitating disease for which psilocybin demonstrates a significant increase in efficacy in relation to existing AUD drugs. Conditional authorization of a new medicine, known as NOC/c in Canada and CMA in Europe, allows the marketing of a new drug with the condition that the sponsor undertake additional studies to verify the clinical benefit. Under NOC/c and CMA, companies are required to conduct confirmatory studies to validate the initial efficacy evidence. Clairvoyant intends to launch a pivotal confirmatory trial in H2 2025, with a read out in 2027, to support full approval of psilocybin treatment in Canada, the EU and UK.

About Patient Safety
Clairvoyant is committed to ensuring the safety and well-being of participants. Participants are supported by two therapists in preparation for, and during, the psychedelic experience induced by psilocybin. Clairvoyant has trained over 50 therapists in its 35-hour training program. Therapists are monitored for adherence to the trial protocol and ethics under Clairvoyant's industry leading therapist adherence monitoring program. No ethical concerns have been identified to date.

About Alcohol Use Disorder
Alcohol is the leading risk factor for overall burden of disease among men and a significant risk factor among women.[ii] A regional study recently reported that fewer than 5 per cent of patients diagnosed with moderate to severe alcohol use disorder receive recommended medications.[iii]

About Clairvoyant Therapeutics
Clairvoyant Therapeutics is a Canadian biotechnology company trailblazing a path to global mental health through psilocybin treatment. Clairvoyant's speed-to-market clinical strategy is designed to enable psilocybin treatment in Canada, EU & the UK for patients living with Alcohol Use Disorder (AUD) beginning in 2025.

The company's exceptional team, with deep clinical development experience, has made Clairvoyant the most advanced company developing psilocybin for the treatment of AUD. Clairvoyant is a member of Life Sciences BC.

Additional information about Clairvoyant's clinical trial may be found at ClinicalTrials.gov

-30-

For more information:
Damian Kettlewell
damian@clairvoyantrx.com


[i] Bogenschutz, MP et al. (2022) JAMA Psychiatry. 2022;79(10):953-962. doi:10.1001/jamapsychiatry.2022.2096

[ii] World Health Organization. Global Status Report on Alcohol and Health 2014 Accessed March 2024 at WHO Global Status Report on Alcohol and Health 2014



View the original press release on accesswire.com

More from this category

  • Biotechnology, Environment
  • 18/04/2024
  • 11:03
Wilderlands

Wilderlands protects 100,000 square metres of vulnerable Australian habitat through biodiversity credits.

Wilderlands have reached a major milestone becoming the world’s fastest voluntary biodiversity credit developer to retire over 100,000 units which will protect over 10…

  • Contains:
  • Biotechnology
  • 18/04/2024
  • 00:22
Derm-Biome Pharmaceuticals, Inc

Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 million Americans a year developing this condition. Treating AKs before the cells become cancerous and spread to other parts of the body is crucial. For those patients with multiple AKs, common treatment options are chemotherapy creams and photodynamic therapy. Although effective, these treatments come with significant side effects, such as redness, blistering, and peeling, with recovery times that can be lengthy and uncomfortable. The global actinic keratosis treatment market size is projected to reach as high as $10 billion USD by 2031, fuelled by increasing cases of AK and rising healthcare spending.Derm-Biome Pharmaceuticals is a Vancouver-based biopharmaceutical…

  • Biotechnology, Medical Health Aged Care
  • 16/04/2024
  • 11:26
Island Pharmaceuticals

Island reports highly positive new data from ISLA-101 Single Ascending Dose study

Island reports highly positive pharmacokinetic data and reconfirms strong safety / tolerability data for ISLA-101 from its 24-subject Single Ascending Dose clinical study Data analysis shows required levels of ISLA-101 concentration in the blood were observed after only a single dose, achieving the study's purpose This important new data is being used to prepare for Island's planned Phase 2a clinical trial in dengue fever MELBOURNE Australia, 16 April 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to announce highly encouraging pharmacokinetics (PK) data from its ISLA-101 Single Ascending Dose study. ISLA-101 is…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.